Ocular Pressure in Steroid-treated Dermatology Patients
Ocular hypertension and glaucoma are eye conditions associated with abnormally high fluid pressure in the eye (called intraocular pressure or IOP). If left untreated, the elevated IOP may eventually cause damage to the nerve of the eye and potential impairment of vision.
The use of certain drugs has been identified as a risk factor for raised IOP, including various forms of administration of corticosteroids. Corticosteroids can also lead to cataract, which is clouding of the lens in the eye that can affect vision.
In this research study, we would like to find out whether the use of corticosteroids in our dermatology clinic leads to raised IOP, in order to identify patients at risk and to allow them to be more closely monitored than others. It is important to identify those patients who have a corticosteroid-induced pressure rise early enough to prevent them from permanent glaucomatous visual loss.
Topical Corticosteroid-treated Dermatology Patients
Drug: Potent topical steroid
Drug: Superpotent topical steroid
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Intraocular Pressure in Corticosteroid-treated Dermatology Patients|
- Change in intraocular pressure from baseline [ Time Frame: after 1, 2 and 3 months ] [ Designated as safety issue: No ]Measurements will be done at 28 (+/- 7 days) days, 56 (+/- 7 days) days, and 90 (+/- 7 days)days after initiation of topical steroids.
- Whether there is any clinical evidence of cataract at the final visit of the study. [ Time Frame: After 1, 2 and 3 months ] [ Designated as safety issue: No ]Measurements will be done at 28 (+/- 7 days) days, 56 (+/- 7 days) days, and 90 (+/- 7 days)days after initiation of topical steroids.
|Study Start Date:||September 2012|
|Study Completion Date:||July 2013|
|Primary Completion Date:||July 2013 (Final data collection date for primary outcome measure)|
Potent topical steroid-treated
Patients treated with potent topical steroids
|Drug: Potent topical steroid|
Superpotent topical steroid-treated
Patients treated with superpotent topical steroids
|Drug: Superpotent topical steroid|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01759914
|University Hospitals Coventry and Warwickshire NHS Trust|
|Coventry, West Midlands, United Kingdom, CV2 2DX|